An adaptive phase I/II randomized placebo-controlled trial to determine safety, immunogenicity and efficacy of non-replicating ChAdOx1 SARS-CoV-2 vaccine in South African adults living without HIV; and safety and immunogenicity in adults living with HIV

  • Funded by South Africa Department of Science and Innovation, South African Medical Research Council (SAMRC)
  • Total publications:0 publications
Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    N/A
  • Known Financial Commitments (USD)

    $700,000
  • Funder

    South Africa Department of Science and Innovation, South African Medical Research Council (SAMRC)
  • Research Location

    South Africa
  • Lead Research Institution

    N/A
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation
  • Research Subcategory

    Phase 1 clinical trial
  • Special Interest Tags

    N/A
  • Study Type

    Clinical
  • Clinical Trial Details

    Clinical Trial, Phase I
  • Broad Policy Alignment

    Pending
  • Age Group

    Adults (18 and older)
  • Vulnerable Population

    Individuals with multimorbidity, Other
  • Occupations of Interest

    Unspecified

Abstract